FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.

@article{PalatnikdeSousa2008FMLVA,
  title={FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.},
  author={Clarisa Beatriz Palatnik-de-Sousa and Andr{\'e} de Figueiredo Barbosa and Sandra Maria Oliveira and Dirlei Nico and Robson Ronney Bernardo and Wania Renata Santos and Maur{\'i}cio Rodrigues and Irene da Silva Soares and Gulnara Patr{\'i}cia Borja-Cabrera},
  journal={Expert review of vaccines},
  year={2008},
  volume={7 6},
  pages={833-51}
}
The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical and clinical (Phase I-III) vaccine trials against canine visceral leishmaniasis (92-95% of protection and 76-80% of vaccine efficacy) when formulated with a QS21 saponin-containing adjuvant. It became the licensed Leishmune vaccine for canine prophylaxis in Brazil. The immune response raised by the vaccine is long lasting, immunotherapeutic and reduces dog infectivity blocking the transmission of the… CONTINUE READING
Highly Cited
This paper has 37 citations. REVIEW CITATIONS